Shares of Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) traded up 2.6% during trading on Thursday . The stock traded as high as $4.47 and last traded at $4.38. 23,065 shares traded hands during trading, an increase of 965% from the average session volume of 2,165 shares. The stock had previously closed at $4.27.
Graybug Vision Stock Performance
The firm’s 50 day moving average price is $4.44 and its two-hundred day moving average price is $4.65. The company has a market cap of $6.88 million, a P/E ratio of -0.18 and a beta of 1.20.
About Graybug Vision
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
See Also
- Five stocks we like better than Graybug Vision
- Russell 2000 Index, How Investors Use it For Profitable Trading
- When Is the Best Time to Invest in Mutual Funds?
- What Makes a Stock a Good Dividend Stock?
- Is NVIDIA Stock in a Correction or Consolidation?
- What is Forex and How Does it Work?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
